Acquisition

Medtronic to buy Contego Medical for $380M to grow vascular portfolio

What's the deal? Medtronic has agreed to acquire Contego Medical, a privately held developer of treatments for carotid artery disease and peripheral vascular conditions, in a deal valued at $380 million plus potential post-acquisition payments. The acquisition expands Medtronic's vascular technology portfolio.

Why now? The two companies struck an exclusive US distribution agreement in January 2025. This deal converts that relationship into ownership, giving Medtronic full control of technologies it already sells in the US.

What's the endgame? The acquisition adds Contego's carotid revascularization and thrombectomy technologies to Medtronic's cardiovascular offerings. A central component is the recently FDA-approved Neuroguard IEP Direct System, which the companies describe as the first transcarotid artery revascularization system combining integrated embolic protection with flow reversal.

The deal also includes Contego's Excipio thrombectomy devices, which remove blood clots obstructing circulation. They will complement Medtronic's existing Liberant thrombectomy system in treating peripheral vascular disease.

The clinical case: Contego reported results from its PERFORMANCE III study of the Neuroguard IEP Direct System. At 30 days, the study reported zero strokes, neurological deaths, cranial nerve injuries, and myocardial infarctions among evaluated participants. The company notes those findings relate to the specific study population and do not guarantee equivalent results in all patients.

What could go wrong? The deal remains subject to customary closing conditions and is expected to close in the third quarter of Medtronic's fiscal year. Medtronic expects the transaction to be minimally dilutive to adjusted earnings per share in fiscal 2027 and fiscal 2028, before becoming neutral to accretive later.

The signal: Carotid artery disease narrows the vessels supplying the brain and can raise stroke risk, but revascularization procedures can themselves release debris — the challenge Contego's embolic protection targets. For Medtronic, which employs more than 90,000 people across more than 150 countries, the deal reflects a strategy of targeted bets that deepen its core device franchises rather than open entirely new markets.

Read more: pulse2.com

Image credit: Contego Medical

More top stories